· drug discovery & development readers focus on pharmaceutical and biopharmaceutical...

www.dddmag.com

2013Integrated MediaPlanning Guide

Overview Circulation Editorial Calendar Digital Website Enewsletter Custom

Print Magazines:

• Inserts/Outserts

• Supplements

• Marketplace/Classifieds

• Coverwraps

• Bellybands

• Custom Publishing

Direct Mail

list rentals

aDvertising OPPOrtunities...the BuilDing BlOcks

weB:

• www.dddmag.com

• Banners

• Keywords

• White Papers

• Video and Rich Media

• Podcasts

• Storefronts

weBcasts:

• Video

• Audio

Digital:

• Daily Update and Early Report Enewsletters

• CRO Report Enewsletter

• Custom Enewsletters

Print advertising is the cornerstone in any marketing campaign. It’s the first and longest lasting impression of any advertising medium. Reaching a loyal group of subscribers, it’s also the most credible form of advertising. Drug Discovery & Development offers several vehicles for advertising beyond its print magazine, special supplements and guides. For high-visibility and high-impact advertis-ing, outserts, coverwraps, bellybands, and other custom publishing options are available.

The greatest benefits of Web advertising are unlimited content space, trackable results, and the ability to extend the viewers’ interest and conduct commerce. Drug Discovery & Development’s Website— www.dddmag.com—offers an array of advertising solutions at every budget level, from traditional buttons and banners to educational videos.

Digital advertising offers the fastest response to your marketing message. E-newsletters and e-blasts also offer advertisers some of the highest return on their dollar. The Direct Marketing Association recently estimated that e-newsletter marketing returned $57.25 for every one dollar spent. Several e-newsletter and e-blast options with full contact lead generation reporting are offered. Webcast registrants are a highly qualified audience, proactively engaged in learning more about specific products and companies. Combine this activity with purchasing approval power and your marketing message is delivered to a group poised to purchase.

The key to a successful direct mail marketing package is a targeted, quality list. Demographic list selections that include job title, business/industry, buying influence, etc. are available. Direct mail is a personal approach to marketing with results that are measured and quantified.

www.dddmag.com

integrated media...The Process of Building Your Brand


TOTAL CIRCULATION: 35,516*

Drug Discovery & Development readers work in the pharmaceutical, biopharmaceutical, and biotechnology firms with a single focus on developing strategies and driving drug discovery technologies to market. More than 65% of our 35,516 subscribers are researchers and scientists dedicated to pharmaceutical and biopharmaceutical

investigation, including life science research in pre-discovery. Their mission: to identify and validate targets, identify lead compounds, conduct safety testing, optimize leads, conduct preclinical tests, and explore drug delivery options. They are also responsible for clinical trials implementation and biomarker development.

DRUG DISCOVERY & DEVELOPMENT SUBSCRIBER JOB TITLES*

20.7%

30.1%

33.5%

6.5%

2.5%6.1%

Other 213 0.6%

Process Engineer – Production,

Manufacturing 2,177Purchasing Agent/

Manager 883

Professional/Technical

Consultant 2,293

Staff Scientist 11,899 Lab Management,

Informatics Specialist 10,687

Corporate Management 7,364

DRUG DISCOVERY & DEVELOPMENT SUBSCRIBER BIOSCIENCES/INDUSTRIES*

33.3%

10.5%24.0%

6.1%

2.9%

11.2%

4.8%

Other 272

.08%

Manufacturer 2,282 Hospital/Medical

Center 1,700

University/Academic

3,979

Government Laboratory

1,039

Contract Research

Organization 2,152

Biotechnology 8,528 Biopharmaceutical

3,737

Pharmaceutical 11,827

6.4%

CirCulation overview

*Publisher’s Own Data, August 2012.

www.dddmag.com


Bonus International Publication Circulation Subscribers

Africa 81

Asia 1,162

Asia Pacific 50

Central America 62

Europe 1,046

Middle East 93

North America 296

South America 118

Total Bonus Publication Circulation 2,908

actions taken based on seeing an adveRtisement in dRug discoveRy & development:

publication that best deliveRs pRactical solutions, Rapidly changing technologies, and

effective ways to be moRe pRoductive:

n DRug DiScOveRy & DevelOPmeNT: 68.1%

n Science: 4.2%

n geN: 4.2%

n Nature: 4.2%

n BioTechniques: 8.3%

n DDN: 5.6%

n Other: 5.6%

77.9%

29.4%

39.7%33.8%

25.0%

17.6%dRug discoveRy &

development 68.1%science

4.2%

gen 4.2%

nature 4.2%

biotechniques 8.3%

other 5.6%ddn

5.6% n visited advertiser’s Website: 77.9%

n Discussed ad with others: 29.4%

n Passed ad along to others: 39.7%

n Filed ad for future reference: 33.8%

n Recommended a product: 25.0%

n e-mailed or called advertiser: 17.6%

top subscRibeRs by company

company count

merck . . . . . . . . . . . . . . . . . . . . . 610Pfizer . . . . . . . . . . . . . . . . . . . . . 483Abbott laboratories . . . . . . . . . . 340Bristol myers Squibb . . . . . . . . . . 248Wyeth . . . . . . . . . . . . . . . . . . . . . 247glaxoSmithKline . . . . . . . . . . . . . 221eli lilly . . . . . . . . . . . . . . . . . . . . 210university of california . . . . . . . . 192Amgen . . . . . . . . . . . . . . . . . . . . 162Baxter Healthcare . . . . . . . . . . . . 112Boehringer ingelheim . . . . . . . . . 106Novartis . . . . . . . . . . . . . . . . . . . 102

company count

university of Texas . . . . . . . . . . . . 95university of Pennsylvania. . . . . . . 90Hoffman laRoche inc. . . . . . . . . . . 86genzyme . . . . . . . . . . . . . . . . . . . 85AstraZeneca Pharmaceuticals . . . . 83Johnson & Johnson . . . . . . . . . . . 82genentech . . . . . . . . . . . . . . . . . . 80Alcon labs inc. . . . . . . . . . . . . . . . 79Sanofi Aventis . . . . . . . . . . . . . . . . 72Johns Hopkins university . . . . . . . 61massachusetts general Hospital . . 60Roche . . . . . . . . . . . . . . . . . . . . . . 59

company count

university of Pittsburgh . . . . . . . . . 58Washington university. . . . . . . . . . 58university of Florida . . . . . . . . . . . 57Allergan inc. . . . . . . . . . . . . . . . . . 53NiH . . . . . . . . . . . . . . . . . . . . . . . . 52cephalon inc. . . . . . . . . . . . . . . . . 49Northeastern university . . . . . . . . . 49university of Washington . . . . . . . . 49Bayer corp. . . . . . . . . . . . . . . . . . . 48Biogen idec . . . . . . . . . . . . . . . . . . 48Baylor college of medicine . . . . . . 47Harvard university . . . . . . . . . . . . 47

company countSouthern Research institute . . . . . 47Beckman coulter inc. . . . . . . . . . . 46case Western Reserve university . 46Duke university . . . . . . . . . . . . . . . 46emory university . . . . . . . . . . . . . . 46university of Alabama . . . . . . . . . . 46Barr laboratories inc. . . . . . . . . . . 45university of cincinnati . . . . . . . . . 44Scripps Research institute . . . . . . 41university of iowa . . . . . . . . . . . . . 41

SubScriber overview

Source: Publisher’s data.

www.dddmag.com


Drug Discovery & Development readers focus on pharmaceutical and biopharmaceutical research, including life science research in prediscovery. The core focus for many researchers and readers is to identify and validate targets, identify lead compounds, conduct safety tests, optimize leads, conduct preclinical tests, and explore drug delivery options. Our readers also are responsible for clinical trials implementation and biomarker development.

ResouRces used to keep cuRRent with the latest in dRug discoveRy and development technology:

n Print Publications: 80.5%

n Websites: 68.8%

n e-Newsletters: 61.0%

n e-Advertising: 10.4%

n RSS Feeds: 2.6%

n Other: 2.6%

80.5%

68.8%61.0%

10.4% 2.6% 2.6%

what dRug discoveRy & development ReadeRs aRe saying…

publication Read most RegulaRly:

n DRug DiScOveRy & DevelOPmeNT: 57.9%

n Science: 6.6%

n geN: 1.3%

n Nature: 6.6%

n Biotechniques: 5.3%

n DDN: 2.6%

n international Drug Discovery: 6.6%

n Other: 13.2%

Drug Discovery &

Development 57.9%

science 6.6%

gen 1.3%

nature 6.6%

biotechniques 5.3%

ddn2.6%

american drug discovery

6.6%

other13.2%

Source: Publisher’s data.

SubScriber overview

90.6% peRcentage of dRug discoveRy

& development subscRibeRs Reading eveRy issue guaranteed circulation: 35,513 total audience: 51,450

90.6%

www.dddmag.com


2013 Editorial CalEndar

ISSUE January/February March/April CRO Resource Guide May/June July/August September/October November/December

Ad Closing January 18, 2013 March 18, 2013 April 19, 2013 May 17, 2013 July 22, 2013 September 20, 2013 November 18, 2013

Materials Due January 25, 2013 March 25, 2013 April 26, 2013 May 24, 2013 July 29, 2013 September 27, 2013 November 28, 2013

Cover Story Automation Companion Diagnostics Special Supplement: Annual CRO

Resource Guide

Corporate profiles,

capabilities directory, case studies, and more

Mass Spec Antibodies in vivo Imaging UHPLC

Instrumentation — Microscopes Microplate Readers Spectrophotometers Safety Cabinets Flow Cytometry

Assay Development Proteomics Assays ELISA Lead Identification Luminescence Assay Multiplexing Label-free Assay

Cell-Based Tech Cell Culture Apoptosis Biosimilars Cell Lines High-Content Screening Stem Cells

Chemical-Based Tech Compound Libraries Compound Management Contract Chemistry in silico Modeling Virtual Screening Medicinal Chemistry

Informatics PK Modeling Image Analysis Trial Software ELNs — Sequencing Software

Genomics/Proteomics PCR Sequencing Genotoxicity Gene Expression MicroRNA —

Drug Safety High-Throughput

Screening

ADME — Drug-Drug Interfaces Animal Studies Preclinical Studies

Drug Formulation/

Delivery

Nanotechnology Stability Studies Delivery Technologies Bioavailability Dosing Testing Services

Clinical Trials Off-Shore Trials — Adverse Events Trial Reporting Scale Up Trial Management

Tech Advances Biomarkers Histopathology Bioreactors Microfluidics Labeled Assays LIMS

Drug Pipeline GPCR Kinases DNA/RNA Ion Channel Nuclear Receptor Antibodies

Departments • Policy & Projection

• CRO Watch

• New Technologies

• Policy & Projection

• CRO Watch



• CRO Watch



• CRO Watch



• CRO Watch



• CRO Watch


Show Coverage • SLAS

• Pittcon

• AACR

• INTERPHEx

• ASMS

• AAPS Biotech

• DIA

• AAPS

• SFN

• ASCB

www.dddmag.com


1/2 Page Vertical:

Bleed: 4 5⁄8″ × 11 1⁄8″Live: 3 7⁄8″ × 10″

Trim: 4 3⁄8″ × 10 7⁄8″

1/4 Page Vertical:

1 3⁄4″ × 10″

No Bleed

1/4 Page Square:

3 7⁄8″ × 4 3⁄4″

No Bleed

1/3 Page Horizontal:

8 1⁄4″ × 3″; No Bleed1/3 Page Vertical:

2 1⁄2″ × 10″; No Bleed

1/3 Page Island:

3 7⁄8″ × 6 1⁄2″; No Bleed1/3 Page Square:

4 3⁄4″ × 4 3⁄4″; No Bleed

2/3 Page

1/2 Page 1/3 Page 1/4 Page

Bleed: 6″ × 11 1⁄8″Live: 5 1⁄4″ × 10″Trim: 5 3⁄4″ × 10 7⁄8″

Bleed: 9 1⁄4″ × 11 1⁄8″Live: 8 1⁄4″ × 10″

Trim: 9″ × 10 7⁄8″

Full Page

1/2 Page Horizontal:

Bleed: 9 1⁄4″ × 5 1⁄4″Live: 8 1⁄4″ × 4 3⁄4″Trim: 9″ × 5″

1/2 Page Island:

5 1⁄4″ × 7 1⁄2″(shown with dotted line)

print aDVErtiSinG DimEnSionSwww.dddmag.com

Bleed: 18 1⁄4″ × 11 1⁄8″Live: 17″ × 10″ Trim: 18″ × 10 7⁄8″

Full Page Spread

Contact your Drug Discovery & Development representative for rates.

Click here to view complete digital advertising specifications.


http://www.advantagebusinessmedia.com/ims/pdf/ABM_PrintAdSpecs.pdf

drug discovery & development’s digital extra Digital Extra is an interactive, bi-monthly e-magazine series produced by the editorial staff of Drug Discovery & Development. This tightly-focused publication presents must-read articles, high-level research development news, drug developments, partnering and collaborations, the business of drug discovery and development, and NIH and FDA news.

An important component of Digital Extra’s coverage is Industry Snapshot. This feature series addresses current topics as answered by some of the industry’s key players.

Digital Extra creates the perfect complementary editorial environment for your message, reaching 50,000 subscribers involved in the life sciences and drug development. And, equally as important, it delivers the critical element required to grow your business—sales leads.

In addition to traditional print-based advertising, Digital Extra incorporates interactive media presentation opportunities, including video and other rich media options. Lead tracking on all ads and multimedia messages is offered for three full months. Advertisers will receive monthly leads based on overall visits, opens, page views, time spent, pages visited, and contact leads for zoomed or enlarged views. A fully-supported marketing campaign will assist in generating traffic, views, and a constant flow of new leads during the three-month exposure period.

month topic ad closing deployment newsletter coverage

January Automation January 4 January January 24 - February 7

March Instrumentation February 20 March 20 March 21 - April 5

May Research Tools April 19 May 15 May 16 - 31

July Partnering June 21 July 17 July 18 - August 2

September CROs August 13 September 18 September 19 - October 4

November Informatics October 17 November 13 November 14 - December 6

2013 publishing/deployment schedule

digital extrawww.dddmag.com


www.DDDMAG.coMDrug Discovery & Development ’s Website covers the latest technology and tools for pharmaceutical and biopharmaceutical research labs around the world. The site offers a wealth of information for researchers/scientists and across these market sectors including:

• Headlines – A comprehensive and live daily news feed delivers breaking global news on the life sciences and technology.

• New Technologies – Information on the latest new technologies driving drug discovery to market including new products, cell biology, technology, chromatography, automation, software, and instruments.

• Recommended Reading – A collection of features, articles, technical papers and more presenting in-depth information on major challenges and solutions associated with drug development and drug discovery.

• Now in Drug Discovery & Development – A searchable archive of magazine and website features dealing with, drug discovery, drug development, genomics & proteomics, policies & projections, and technology advances.

• Multimedia (including videos, webcasts, and podcasts).

Drug Discovery & Development ’s website, with more than 100,000 unique visitors and 350,000 page views monthly, can help you meet your strategic marketing goals, including brand/company awareness, lead generation, traffic building, product introduction, and technological education.

Sponsorships are run-of site, with numerous options available, including customized exposure packages. All site sponsorships include complete lead generation and tracking information for follow-up with potential customers.

websitewww.dddmag.com


Advertising options & rAtes Drug Discovery & Development’s website can help you meet your strategic marketing goals, including brand/company awareness, lead generation, traffic building, product introduction, and technological education. Numerous sponsorship options are available, including customized exposure packages.

website aDVeRtisiNG Rates

Ad specsFile format: .gif, .jpg, .swf, or redirect tags (.gif can be animated). Maximum file size: 90 kb. Rich Media: looping animation and Flash included. Other rich media quoted upon request. When sending in Flash, include .fla file (for lead tracking), .swf, and alternate .gif or .jpg. Be sure to include linking URL for ad units.

expandable AdsTwo files are needed (closed and open) .jpg or .swf (.swf should have as little action scripting as possible). Maximum file size is 90 kb each. Drug Discovery & Development will add the close & click URL redirect tags.

www.dddmag.com

Leaderboard728 x 90 pixels

slidable Billboard970 x 30 pixels closed970 x 418 pixels open

peel Back100 x 100 pixels closed500 x 500 pixels open

tower (4 positions)160 x 600 pixels

expandable tower160 x 600 pixels closed300 x 600 pixels open (opens to the left)

Boom Box (3 positions)300 x 250 pixels

expandable Boom Box300 x 250 pixels closed500 x 250 pixels open (opens to the left)

Banner Text & image or 468 x 60 pixels

Boom Box (3 positions)300 x 250 pixels


daily E-NEWSlETTERS

Busy researchers “opt-in” to Drug Discovery & Development ’s Early Report and Update enewsletters to stay current on news, technology, and trends. E-newsletters are delivered to your inbox, providing direct links to critical industry information.

Early Report features a broad range of technologies, scientific advances, regulatory news, collaborations, and CRO activities for life science and drug research.

Update reports on the day’s latest headlines, regulatory guidelines, drug development and industry news, as well as new technologies. Update is deployed to 22,000 subscribers with an average open rate of 25%. The average click-thru-rate is 4.9%.

Sponsorships are available on a weekly basis – Monday through Friday. In addition to a full week of exposure and branding, advertisers receive complete contact lead information for all readers that click on their ads, including name, title, company name, and address, and telephone and email information if available.

Ad positions include:

• Leaderboard (728 x 90 pixels)

• Boombox (300 x 250 pixels)

• Primary Text Ads in three positions (50 words of text, 75 x 75 pixel image, and link); 468 x 60 banner also available in these positions

MONTHly E-NEWSlETTERS

CRO Monthly reports on the latest research, partnerships, services, and business activities at contract research organizations.

•

•

leaderboard (798 x 90 pixels)$2,950 net per week

Boombox (300 x 250 pixels)$2,600 net per week

Primary Text ads or Banner (50 words, 75 x 75 image, URL link, or 468 x 60 pixels)$2,400 net per week

Secondary Text ads or Banner (50 words, 75 x 75 image, URL link, or 468 x 60 pixels)$2,000 net per week

e-newsletterswww.dddmag.com


webcasts

Webcast Topics Planned for 2013:

• In Silico Modeling

• Companion Diagnostics

• iPS Cells

• Monoclonal Antibodies

• Live-Animal Imaging

• Next-Generation Sequencing

The Webcast series is just one of the many informative and valuable tools found at www.DDDmag.com. Drug Discovery & Development

can also work with you to develop custom webcasts based on your suggestions and expertise.

SPonSored Webinar oPPorTuniTieS

Your representative can work with you to help you position your company as a thought leader with a cost-effective sponsorship of a turnkey

Drug Discovery & Development Webcast.

www.dddmag.com

Drug Discovery & Development’s professionally planned educational webcasts result in highly successful, well-attended sessions covering topics that affect scientists and engineers. Each engaging, interactive forum features an expert panel and an interactive audience via live Q&A and polling. Webcast sponsorships provide a dynamic marketing solution that accelerates your lead generation process and drives actionable results.

Webcast sponsors benefit from a highly-visible interactive marketing campaign that includes print advertising and comprehen-sive branding via the Web and electronic newsletters, as well during the live event. Sponsors also receive complete registration and attendance data for the live date and subsequent on-demand viewing period when electronic design engineers can experi-ence the webcast when its convenient based on their busy schedule. Exclusive and shared sponsorship events are offered.


ExclusivE E-nEwslEttEr sponsorship This e-newsletter is developed by our editors based on your product or application areas. Content is culled from the pages of Drug Discovery & Development or other Advantage Business Media Science publications. Advertising/Sponsor content is included and sent to the entire electronic mailing list. This cost-efficient marketing approach leaves a lasting impression to readers, but also supplies your company with instant results. Credibility, pertinent content and new product information are a winning ROI formula for e-newsletters.

custom E-nEwslEttEr sponsorshipCustom e-newsletters give our advertisers more freedom in terms of supplying all or a portion of the content, along with advertising material. Custom sponsorships are limited to third-party mailing lists—which are restricted to four mailings per month. Contact your account manager to learn more about Custom e-marketing opportunities.

E-markEting blastsDrug Discovery & Development ’s exclusive e-marketing blasts allow you to add significant stopping power and impact to your sales and marketing campaign. Your personalized e-blast will help you educate and inform a top-level audience of Drug Discovery & Development subscribers and build excitement with an opportunity-specific message.

lEad gEnEration programAdvertisers in Drug Discovery & Development gain access to the Advantage Lead Generator Program—an innovative program that delivers ROI with qualified sales leads. Our lead generation experts:

• Uncover the decision-makers

• Qualify the buying need for an advertiser’s product or service category

• Define a buying timeline for that purchase

• Deliver full contact sales leads.

advantagE adintEll studiEsAdvertisers gain comprehensive analysis from readers/buyers to improve the effectiveness of their advertising. What is an Advantage AdIntell Study? A thorough evaluation of an

advertisement’s attention-getting ability, credibility, overall informational value, and more importantly, the targeting power is has over your competition.

How it works: Advertisements in the June and November/December issues will be evaluated by readers. Both quantitative and qualitative feedback will be obtained. Readers will be asked for feedback on whether or not each advertisement was effective in key areas of advertising: attention-getting ability, believability, and informational value. Readers will also provide feedback by responding with verbatim comments on what message or feeling they get from an advertisement. Advertisers will discover ways to communicate more effectively with Drug

Discovery & Development readers, thus enhancing the return on every advertising investment.

Applying the results. The goal of any advertising awareness study is the application of results and feedback into the creation of an optimum advertising message. AdIntell Studies create a message and image that is targeted and relevant. The right advertisement increases awareness, image, and reader action.

CUSTOM E-MARKETING

Drug Discovery & Development offers several options of custom e-marketing. Whether you’re looking for a monthly content-based sales vehicle to send to your customer base, or a one-time lead-generating e-newsletter, our staff is ready to assist you. Some custom marketing opportunities, include our full electronic mailing list; others may exclude “opt-outs” third-party e-lists.

www.dddmag.com


Editorial StaFF

Group Publisher Sofia Goller 973-920-7051 [email protected]

Editorial director Rita C. Peters [email protected]

Editor Peter A. Bennett [email protected]

Publishing Headquarters 100 Enterprise Drive, Suite 600Box 912Rockaway, NJ 07866-912973-920-7000 www.dddmag.com

publishing Team

SalES & Production StaFF

East coast Greg Renaud 973-920-7189; Fax 973-920-7542 [email protected]

West coast Jordan Bender 973-920-7480; Fax 973-607-5498 [email protected]

administrative assistantAna [email protected]

Web Production SpecialistShannon [email protected]

Print Production ManagerAngela Coleman 973-920-7155; Fax [email protected]

www.dddmag.com


· drug discovery & development readers focus on pharmaceutical and biopharmaceutical...

Documents